| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00793338 Details | 2023-06-26 Interventional | 4 | 0 | Sildenafil Citr… Heart Failure | The project was not funded and could not be initiated. - | |||
| NCT04995978 Details | 2023-06-23 Interventional | 2 | 0 | Pioglitazone Insulin Resista… Prostatic Neopl… Prostate Cancer | No participants were recruited and the study was deemed not feasible - | |||
| NCT04987294 Details | 2023-06-23 Interventional | 2 | 19 | Rasburicase Gout Hyperuricemia Kidney Diseases Renal Insuffici… Chronic Kidney … | Company Financing - | |||
| NCT04502433 2020-002632-75 Details | 2023-06-23 Interventional | 2 | 22 | Poractant alfa Acute Lung Inju… Respiratory Dis… Respiratory Dis… Syndrome Acute Respirato… | The enrolment was extended. Nevertheless, despite the Sponsor's attempts, the infection status
did not permit the identification of eligible patients for the study to complete it in a
reasonable time. Once the impact of the Covid 19 pandemic significantly declined and intubated patients with acute respiratory distress syndrome (ARDS) outcome became rare, the Sponsor considered it unfeasible to maintain efforts to recruit further patients into the study. Thus, due to low recruitment, the study was terminated early for non-safety reasons. | |||
| NCT04194034 Details | 2023-06-23 Interventional | 1/2 | 15 | Flucytosine Colorectal Neop… | Study has been terminated after Phase I part on 23 February 2023 - | |||
| NCT03724071 Details | 2023-06-23 Interventional | 1/2 | 51 | Flucytosine Colorectal Neop… Digestive Syste… Gastrointestina… Neoplasms Colorectal Neop… Digestive Syste… | Study has been terminated after Phase I part on 23 February 2023 - | |||
| NCT02554812 2015-002552-27 Details | 2023-06-23 Interventional | 1/2 | 409 | Avelumab Neoplasms Advanced Cancer | The study was terminated since there was no need for further safety or efficacy data to be
collected. The participants having benefit from the Investigational treatments have been moved
to a continuation study (NCT05059522) - | |||
| NCT01308437 Details | 2023-06-23 Interventional | 3 | 134 | Insulin Insulin, Globin… Isophane Insuli… Diabetes Mellit… Type I Diabetes | Business reasons - | |||
| NCT05128773 2021-000398-10 Details | 2023-06-22 Interventional | 3 | 3 | Tamoxifen Breast Neoplasm… Breast Cancer | Sponsor decision to prematurely stop the study, not linked to any safety concern Due to premature discontinuation and closure of study decided by the Sponsor, only safety data were summarized and reported, and no efficacy data was collected. | |||
| NCT04766996 Details | 2023-06-22 Interventional | 4 | 57 | Acetaminophen Aspirin Bupivacaine Diclofenac Ketorolac Trome… Lidocaine Meloxicam Omeprazole Prednisone Pregabalin Propofol Tramadol Tranexamic Acid Opioid-Related … Anesthesia Opioid Use | Loss of surgery team member deemed the study procedures impossible to achieve, and no
replacement could be found in a timely manner to complete trial as initially planned. This study aimed to enroll a total of 170 participants. Due to staffing issues and the coronavirus disease 2019 (COVID-19) pandemic, this trial was terminated early and therefore the retrospective data was not collected. | |||
| NCT04650204 Details | 2023-06-22 Interventional | 4 | 4 | Anticonvulsants Drug Resistant … Epilepsies, Par… Epilepsy Glioma Seizures Intractable Epi… Malignant Gliom… Seizure Disorde… WHO Grade 2 Gli… WHO Grade 3 Gli… | The funding sponsor, EISAI, sold the US rights to the medication and can no longer provide it
to patients for the study. Study was terminated due to the funding sponsor(EISAI) sold the US rights to the medication and can no longer provide it to patients for the study. | |||
| NCT04109482 Details | 2023-06-22 Interventional | 1/2 | 3 | Cyclophosphamid… Fludarabine Neoplasms Blastic Plasmac… | Business reasons. - | |||
| NCT04094584 Details | 2023-06-22 Interventional | 4 | 179 | Naltrexone Alcohol Drinkin… Alcoholism Emergencies Substance-Relat… Alcohol Abuse o… Alcohol Use Dis… Substance Use | 12 month follow up data not collected due to pandemic disruptions - | |||
| NCT03458416 Details | 2023-06-22 Interventional | 2 | 2 | Cannabidiol Prader-Willi Sy… Syndrome | Insys Therapeutics filed Chapter 11 and terminated all studies. This study was terminated by the Sponsor. The Sponsor terminated the study due to slow enrollment and a failure to identify adequate participants that met eligibility criteria. Due to study termination and only 2 participants being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported. | |||
| NCT03399448 Details | 2023-06-22 Interventional | 1 | [1 Refs] | 3 | Cyclophosphamid… Fludarabine Liposarcoma Liposarcoma, My… Multiple Myelom… Sarcoma, Synovi… Melanoma Myxoid/Round Ce… Synovial Sarcom… | Sponsor has terminated trial to pursue other targets. - | ||
| NCT01326312 Details | 2023-06-22 Interventional | 2 | 159 | Leuprolide Prostatic Neopl… Prostate Cancer | FDA Clinical Hold Study terminated early | |||
| NCT00675922 Details | 2023-06-22 Interventional | 2/3 | 98 | Mafenide Silver Nitrate Burns Burn | Data inconclusive. - | |||
| NCT05908513 Details | 2023-06-18 Interventional | 1 | 0 | Acetylcysteine N-monoacetylcys… Atherosclerosis Diabetes Mellit… Inflammation Peripheral Arte… Atherosclerosis… Oxidative Stres… Peripheral Arte… | Lack of available resources needed to conduct study. - | |||
| NCT05553405 Details | 2023-06-18 Interventional | 1 | 0 | Soybean oil, ph… Obesity | No longer able to run study - | |||
| NCT05442684 Details | 2023-06-18 Interventional | 3 | 0 | Vaccines COVID-19 | The trial protocol was not approved by the regulatory authorities. - |